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Abstract
Background: The development of e-Science presents a major set of opportunities and challenges
for the future progress of biological and life scientific research. Major new tools are required and
corresponding demands are placed on the high-throughput data generated and used in these
processes. Nowhere is the demand greater than in the semantic integration of these data. Semantic
Web tools and technologies afford the chance to achieve this semantic integration. Since pathway
knowledge is central to much of the scientific research today it is a good test-bed for semantic
integration. Within the context of biological pathways, the BioPAX initiative, part of a broader
movement towards the standardization and integration of life science databases, forms a necessary
prerequisite for its successful application of e-Science in health care and life science research. This
paper examines whether BioPAX, an effort to overcome the barrier of disparate and
heterogeneous pathway data sources, addresses the needs of e-Science.
Results: We demonstrate how BioPAX pathway data can be used to ask and answer some useful
biological questions. We find that BioPAX comes close to meeting a broad range of e-Science
needs, but certain semantic weaknesses mean that these goals are missed. We make a series of
recommendations for re-modeling some aspects of BioPAX to better meet these needs.
Conclusion: Once these semantic weaknesses are addressed, it will be possible to integrate
pathway information in a manner that would be useful in e-Science.
Background
In this paper, we test the semantic integration capability of
pathway data for e-Science. In particular, we explore the
utility of the BioPAX ontology for providing a common
conceptualization for the semantics of pathway data and as
the mechanism for querying these data. In many aspects,
pathway data form the nexus of industrial scale in silico
biology, and therefore are a microcosm of bioinformatics
within e-Science. We use the BioPAX initiative as an exem-
plar of the kind of semantic activity that enables e-Science
to happen and we explore BioPAX's ability to deliver on
the requirements of e-Science via use of its BioPAX ontol-
ogy. The term e-Science is used to describe both the pur-
suit of global, collaborative in silico science and the
computational infra-structure to support it. There are sev-
eral factors present in the development of e-Science. Typ-
ically, such endeavors are computationally intensive and
are carried out in highly distributed network environ-
ments that tend to use large, heterogeneous data sets [1,2].
The infrastructure that supports such science is often
referred to as the Grid and promotes virtual laboratories
that allow scientists to collaborate and share resources
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without requiring the location of the scientists or the
resources to be in physical proximity. e-Science is inti-
mately linked to Grid computing and bioinformatics is
one example of the kind of science that e-Science encom-
passes [3].
It is easy to see how bioinformatics fits into this paradigm;
it has highly distributed and heterogeneous data, along
with communities of people working together on biolog-
ical problems [3]. Indeed, bioinformatics is moving into a
more computationally intensive era, with high-through-
put experiments being coupled with large-scale systems
biology simulations. The scale, in size and complexity, of
bioinformatics in silico experiments necessitates a transi-
tion from hand-crafted single sequence analyses towards
systems level approaches. e-Science is bringing about the
industrialization of bioinformatics by providing the infra-
structure to support these kinds of in silico experiments.
(Here we take a broad interpretation of bioinformatics to
include the storage, management and analysis of biologi-
cal data needed to answer biological questions.)
In 2002, Stein [4] called for the formation of a "bioinfor-
matics nation" through the adoption of technology such
as Web services. e-Science exploits these programmatic
interfaces to data and uses access to distributed computa-
tional resources, often using workflow technology [5-10]
to automate the systematic operation of large scale analyt-
ical processes.
This kind of industrialization, a result of the high-
throughput processing of data and the supporting infra-
structure, has already been seen, in particular in the
'omics. The catalogues of the genes present in an organism
that are now available for many species in this post genomic
era has provided the foundation for modeling the interac-
tions of genes and their products in the whole cell. In
addition, transcriptome analysis through microarray
experiments has produced large volumes of data which
have been used effectively and have transformed the field
of experimental biology. Coupled with the catalogues of
genes, the further layers of 'omic data has begun to pro-
vide enough information for the systems  approach to
molecular biology.
Pathways and systems biology
The factors described above, computationally intensive
research, highly distributed network environments, cata-
logues of organisms' genes, heterogeneous data sets, etc.,
have come together to create a situation where informa-
tion about biological networks, of which pathways are
fragmentary views, is both the goal of biology and the
means through which biologists ask questions.
For most biologists, these networks are conceptualized as
fragments or views of parts of the in vivo cellular network.
These fragments are the commonplace pathways seen in
numerous papers, presentations and text-books. It is
important to remember, however, that they are a concep-
tualization; simply a way that biologists describe the cel-
lular molecular domain. Nevertheless, they form a point
at which genes, gene products, small molecules, reactions,
etc. all come together in a virtual organization. Pathways
are the fundamental form that knowledge must take for
the needs of systems biology; the entities in pathways and
the data, such as equilibria, rate constants, etc. are all vital
for the pursuit of systems biology.
The move towards systems biology has begun to capitalize
on the availability of genomic and other information to
start mathematically modeling genetic, metabolic and
macro-molecular (both regulatory, signaling and meta-
bolic) networks. Data on these networks are recorded as
pathways. These pathway models emphasize systems of
components rather than the components themselves. It is
possible only because the information that has been gath-
ered by molecular biologists over the past twenty years is
now readily available.
Pathways are the nexus, the semantic communication
point in this endeavor. If we are to model genetic, meta-
bolic and macromolecular networks, then we have to
assemble our knowledge from pathway data to reform
these networks. e-Science infra-structure is necessary for
an industrial approach to systems biology, but it is not in
itself sufficient. Unless the data can be co-ordinated, espe-
cially at a semantic level, the wealth of biological data will
not offer up its knowledge to biologists. It is vital, there-
fore, that we can reliably interpret the semantics of molec-
ular biological data, particularly at the pathway level.
Unfortunately, pathway information is scattered across
many disparate database resources and tends to be con-
ceptualized in different ways, each with its own semantic
and syntactic representation. Metabolic pathways capture
the precise way in which one molecule is converted into
another in a series of biochemical reactions; molecular
interaction databases are typically binary relationships,
such as protein-protein interactions, or protein-DNA
interactions; gene regulatory networks will represent the
connections between transcription factors and the genes
whose transcription they activate or repress. Signaling
pathway representations, which capture the ways in which
cells respond to their environment can range from vague
or general representations of the form "there's an activa-
tion chain in which A activates B activates C" to specific
and detailed representations involving a series of complex
binding reactions and protein post-translational modifi-
cations.BMC Bioinformatics 2007, 8(Suppl 3):S3 http://www.biomedcentral.com/1471-2105/8/S3/S3
Page 3 of 21
(page number not for citation purposes)
For all these pathway data to be of use to systems biology
efforts and e-Science, the following requirements must be
met:
• Common conceptual framework. A common model of
the entities and their relationships is needed so that all the
elements of pathways (pathway steps, reactions, catalysis,
large and small molecules, etc. etc.) are all interpreted in
the same way.
￿ Common instances. Once a common conceptualization
of the things within the domain of pathways and the rela-
tionships among these things is made, the model must be
populated. Each resource will have its own conceptual
framework that holds data. The same data instances will
appear in different resources. When united in one
resource it is necessary to know that instances are not
redundantly represented in any manner. In database
terms this refers to referential integrity.
￿ Common vocabulary. Both the conceptual framework
and the instances it holds need a common vocabulary
with which to refer to 'things' in the model. This will
include common terms for pathways, small and large
molecules; atoms and ions; etc.
￿ Common format. All the data must have the same for-
mat. All resources must present the data model and the
values within that model in a common form with a com-
mon interpretation. XML, RDF, OWL and CSV are all dif-
ferent formats which to a greater or lesser degree can
represent data. This refers to the syntax of the language.
If all pathway resources had these aspects in common, it
would mean that data from any pathway resource, be it
metabolic, regulatory or signaling, could be integrated
and interoperated in order to pose research questions.
A large proportion of the concepts that make up the broad
definition of the systems biology approach are outlined
above. There is, however, no one resource for the network
of macro- and small-molecules, together with genes. The
numerous databases holding subsets of these data need to
be integrated at each level in order to enable systems biol-
ogy in an e-Science context. In the next section, we
describe the BioPAX initiative which aims to define a con-
ceptual framework, or semantic model, that spans these
conceptual domain boundaries and includes the defini-
tion of the requisite common terms and common data
format. This common language would facilitate the
exchange and aggregation of pathway knowledge initially,
and the assembly of this knowledge in new ways in order
to increase the body of scientific knowledge ultimately.
BioPAX
The BioPAX initiative was undertaken to address the
issues of interoperation between pathway data resources.
A BioPAX Workgroup oversees the creation of a formal,
open-source standard for the representation of biological
pathways in a form that can support all pathway data;
thus to provide a common conceptual framework, a set of
common terms and a common format for exchange and
integration. This means that access to all pathway data-
bases in BioPAX format can be achieved with a single
parser. Alternatively parsers would be needed by each user
for each pathway database. The BioPAX initiative also
sought to provide a representation for new data providers
and thereby eliminate the mapping of concepts and terms
from a native database format to BioPAX.
In support of future uses of pathway data, the BioPAX
Workgroup included machine computability among its
design principles [11]. This resulted in the choice of OWL-
DL. OWL-DL enables full use of reasoners [12], which are
software programs that perform inferences based on
Description Logics (DL), a subset of first order logic [13].
Furthermore, OWL-DL enables sound and complete infer-
encing when used by these software reasoners [14,15].
Reasoners can read an OWL file and based on the logical
axioms of the OWL ontology, decide whether that set of
axioms are logically consistent and, in addition, infer sub-
sumption relationships that are not explicitly encoded in
the ontology, for example, it can infer that a certain mol-
ecule is a protein. This is a significant advantage over the
other representations in the management of knowledge
[16].
As OWL was soon to become a W3C recommendation for
the standard web ontology language [17], OWL satisfied
another BioPAX design goal, namely compatibility. Bio-
PAX, wherever possible, would employ existing standards.
In addition, and of great concern to the BioPAX Work-
group was the expressivity of the language. That is, its
capacity to represent complex relationships such as those
found in biology. For example, in XML-Schema [18] or
RDF [19] it is not possible to express that two classes are
disjoint, i.e. that a molecule of DNA cannot be a molecule
of RNA. It is not possible to express that two classes can-
not contain any members in common; that instances that
are of the class DNA are not and cannot be of the class
RNA. On the contrary, OWL has, for a Description Logic,
a wide range of expressivity for describing constraints on
class membership by instances [13,16].
To understand the needs of pathway research within e-Sci-
ence and the issues that arise in meeting these require-
ments, we present an example at each level of pathway
integration mentioned above: conceptual framework,
instances, vocabulary, and syntax. First we show howBMC Bioinformatics 2007, 8(Suppl 3):S3 http://www.biomedcentral.com/1471-2105/8/S3/S3
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pathway database sources differ at each level, then illus-
trate how BioPAX addresses these requirements at each
level.
Different pathway conceptualizations
To illustrate the semantic difference in database conceptu-
alizations, consider the insulin signaling pathway and the
glycolysis pathway shown in figures, 1 and 2, from Bio-
Carta [20]. Interactions in signaling pathways are
described in terms of a cascade of interacting molecules
(or molecular complexes) resulting in a change in some
cellular process in response to some stimuli. Each step in
the pathway involves a different molecule or molecular
complex. Signaling pathways respond to environmental
stimuli, either internal or external to the cell, and carry a
message that causes (signals) a change in the cell's func-
tioning. Contrast this with a metabolic pathway such as
the glycolysis pathway, where one chemical, through a
series of precise steps, is transformed into another chemi-
cal. In the glycolysis pathway, glucose is transformed into
pyruvate. In metabolic pathways, the end product is a
transformed chemical molecule, in signaling pathways it
is the activation or inhibition of a process.
While the difference at a conceptual level may be expected
between such different categories of pathway types, there
are also differences between conceptualizations of path-
ways of the same type, but defined by different research-
ers. Because BioCarta does not make a machine readable
format available, we will exemplify this with the glycolysis
pathway in KEGG [21,22] and HumanCyc [23] (cf. Fig-
ures 3 and 4). Just observing the visual representation, it
is clear that the pathways start with different molecules
and in fact for KEGG there is no obvious starting point.
This is one fundamental conceptual difference; the
researchers themselves have recognized substantial con-
ceptual differences which have resulted in extensive dis-
cussion in the literature [24-27].
To illustrate the issues at the instance, vocabulary, and
syntax levels, we focus on the representation of a single
reaction, E.C. # 5.3.1.9, and compare its representation in
these two databases. One database, HumanCyc, uses the
vocabulary term β-D-glucose-6-phosphate while the other
database, KEGG, uses the vocabulary term β-D-Glucose-
6P. It is clear that we are referring to the same molecule,
i.e. the same real world class of instances, but the vocabu-
lary term used to name these instances differs and while
this difference is insignificant for a human reader it is sig-
nificant for computational processing. The syntax in
KEGG is XML and a biochemical reaction is defined as an
XML ELEMENT. In KEGG reaction elements have two
components, a substrate and a product. The substrate and
product elements each have one required attribute, a
name which is a KEGG identifier. The data instances in the
two resources, for example the representation of β-D-glu-
cose-6-phosphate, obviously refer to the same thing. It is,
however, hard to do this automatically at the computa-
tional level. This semantic integration of data instances
(these are not ontologically instances, but represent types
or classes of things) is one of the deepest problems in the
industrialization of bioinformatics.
In BioCyc, a collection of organism-specific pathway
genome databases (PGDB), including HumanCyc, a bio-
chemical reaction is represented as an ENZYMATIC-
REACTION in OCELOT [28]. Ocelot is a frame-based sys-
tem which uses two slots, namely LEFT and RIGHT to rep-
resent the reactions participants. The OCELOT syntax is an
ASCII flat-file format.
Although there is a clear difference in visual design
between the KEGG and BioCyc glycolysis pathway, funda-
mentally, these are both representations of a biochemical
reaction within a metabolic pathway, and as such, the
underlying conceptualization of the pathway data they
include is very similar, with largely comparable details
accessible by clicking through on the interface.
In this section, we have given an example to show what we
mean by biochemical reactions being represented differ-
ently by different databases at the four levels, conceptual-
ization, instances, vocabulary and syntax. Now we will
describe BioPAX followed by an example of how to repre-
sent one of the biochemical reactions from HumanCyc in
BioPAX. Following this example, you should be able to do
the same for a biochemical reaction from KEGG or one of
the other databases.
Mapping a reaction from HumanCyc to BioPAX
There are two top level classes in the BioPAX ontology:
entity and utilityClass. Entities describe the biology while
the utility classes are there to record knowledge about the
pathway data such as cross references to other databases,
evidence codes, and experimental conditions. Pathways
are a subclass of entity, along with two sibling classes,
interaction and physicalEntity. A pathway has compo-
nents, PATHWAY-COMPONENTS. The PATHWAY-COM-
PONENTS will be instances of the class pathwayStep, a
utility class. Each pathwayStep contains a set of STEP-
INTERACTIONS that describe the physical interactions,
such as catalysis, modulation, biochemical reaction, com-
plex assembly, and transport that make up that step in the
pathway, or another pathway. A pathway, such as glycoly-
sis, MAPK, or apoptosis is composed of instances of inter-
actions. Interactions can occur between entities so that
interactions of interactions and interactions of pathway
can be represented. A note on notation: classes in BioPAX
use camel-back notation; properties are all upper case
with a hyphen separating each word.BMC Bioinformatics 2007, 8(Suppl 3):S3 http://www.biomedcentral.com/1471-2105/8/S3/S3
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Figure 5 shows how the interactions from one step in the
glycolysis pathway are mapped to entity class hierarchy as
defined in the BioPAX ontology. A biochemical reaction
(across figure at bottom) is mapped to the BioPAX Level 2
root class entity (top of the figure). In this biochemical
reaction, there are three instances of the class physicalEn-
tity, of these, two are instances of the class smallMolecule,
β-D-glucose-6-phosphate and D-fructose-6-phosphate,
and one an instance of the class protein, phosphoglucose
isomerase, (enzyme is not explicitly represented as a sub-
class of protein in BioPAX). This biochemical reaction
converts  β-D-glucose-6-phosphate into D-fructose-6-
phosphate. The reaction itself is controlled by the enzyme
phosphoglucose isomerase. Once the physical entities
that participate in the reactions are identified, together
with the interaction roles they play in the reaction, we can
represent them in BioPAX. Thus in BioPAX, an instance is
created of biochemicalReaction with the property LEFT
filled with β-D-glucose-6-phosphate, the property RIGHT
filled by D-fructose-6-phosphate, and E.C.# property
filled with 5.3.1.9. An instance of the catalysis class is cre-
ated with property CONTROLLER filled with phos-
phoglucose isomerase, and the property CONTROLLED
with the reaction name PGLUCISOM-RXN.
Pathways in BioPAX
In the previous section we describe how a reaction within
a pathway is represented in BioPAX. In this section we
look at how pathways are represented. In BioPAX, path-
ways are defined by their components (the property
PATHWAY-COMPONENTS). The components of path-
ways are defined to be any of the classes of interaction,
pathwayStep or pathway. Pathway steps are defined as a
subclass of utilityClass. The utilityClass is defined in the
BioPAX documentation to be a meta-class to assist with
the description of pathways, see the discussion section for
more on this topic. Each pathwayStep defines a property
called NEXT-STEP which provides the order in the path-
way and a list of properties that define the set of interac-
tions that occur at that step. This property is named STEP-
Image showing the human insulin signaling pathway from BioCarta Figure 1
Image showing the human insulin signaling pathway from BioCarta.BMC Bioinformatics 2007, 8(Suppl 3):S3 http://www.biomedcentral.com/1471-2105/8/S3/S3
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Image showing the human glycolysis pathway from BioCarta Figure 2
Image showing the human glycolysis pathway from BioCarta.BMC Bioinformatics 2007, 8(Suppl 3):S3 http://www.biomedcentral.com/1471-2105/8/S3/S3
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INTERACTIONS. The interactions at each step can be any
subclass of the class physicalInteraction (physicalInterac-
tion was added in BioPAX level 2 as a subclass of interac-
tion in anticipation of level 3 where interactions may also
include genetic interactions.) Each of these physical inter-
actions has participants which are instances of the one of
the subclasses of physicalInteraction or instances of the
class physicalEntityParticipant. The class physicalEntit-
yParticipant is also a utilityClass and is used to describe a
physical entity in the context of an interaction. A physical-
EntityParticipant specifies the physicalEntity in the con-
text of an interaction by adding the properties CELLULAR-
LOCATION and STOICHIOMETRIC-COEFFICIENT. Fig-
ure 6 shows the glycolysis pathway from BioCarta [29]
with the aforementioned isomerase reaction highlighted
and separated into BioPAX classes [30].
BioPAX class, instance, vocabulary and syntax
Above we presented the BioPAX class hierarchy and path-
way representation. Now we will look at it from the per-
spective of the levels of integration required for e-Science.
First we want to make clear that the conceptualization as
described above defines BioPAX as an OWL ontology in
terms of its conceptual framework, the instances (called
individuals in OWL), the vocabulary terms and the syntax.
The syntax used for BioPAX is RDF/XML which is a serial-
Image showing part of the human glycolysis pathway from HumanCyc Figure 3
Image showing part of the human glycolysis pathway from HumanCyc.BMC Bioinformatics 2007, 8(Suppl 3):S3 http://www.biomedcentral.com/1471-2105/8/S3/S3
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ization of OWL. OWL and RDF are graph representations,
XML is a tree structure. RDF and OWL must be serialized
when written for export. It is important to note that Bio-
PAX defines the classes in which to represent pathway
data, the instances are provided by the databases.
The major contribution of BioPAX to e-Science is that it
provides a single conceptual framework for the various
multiple conceptualizations of pathway databases, i.e.
metabolic, molecular interaction, signal transduction and
regulatory pathways. It also provides a common format.
While the BioPAX ontology has a common terminology at
the class level, there is no attempt to provide a common
view of instances within those classes. The question then
is, now that we have data from different conceptualiza-
tions of pathways into the BioPAX representation, can we
do in silico science? Can we deliver pathway information
to industrial scale analyses? Does BioPAX fulfill the
requirements set forth in the introduction?
An experiment with BioPAX
In this section, we present some experiments using the
BioPAX ontology; its instance data and Description Logic
reasoning machinery in order to answer questions about
pathways. We shall see if BioPAX can match the needs of
e-Science outlined in the introduction and the goals of
BioPAX itself.
We now have the BioPAX ontology that acts as a common
conceptualization for a large quantity of data. These data
are encoded as instances of the classes in the BioPAX
ontology. In the ontological sense, these are not really
instances. For example, we have ATP as an instance of the
class smallMolecule. The instance in this case and all oth-
Image showing part of the human glycolysis pathway from KEGG Figure 4
Image showing part of the human glycolysis pathway from KEGG.BMC Bioinformatics 2007, 8(Suppl 3):S3 http://www.biomedcentral.com/1471-2105/8/S3/S3
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ers in BioPAX data should be classes. We will see later that
we have to perform some tricks with BioPAX data because
classes are treated as instances.
In OWL, a class represents a set of instances. Classes of
instances are described by placing what OWL calls restric-
tions  upon classes through combinations of properties
and the instances of other classes that act as successors to
those properties. Restrictions  are aptly named as they
restrict what instances can be members of a class. These
restrictions or conditions take two forms:
1. Conditions can be simply necessary conditions; that is,
any instance must fulfill that condition in order to be a
class member. It is not true, however, that fulfilling that
condition is enough to recognize an instance as a member
of that class. For example, all hexokinase proteins phos-
phorylate glucose, but the ability to phosphorylate glu-
cose is not enough to recognize an enzyme as a
hexokinase.
2. Conditions can be both necessary and sufficient condi-
tions for class membership; that is not only must any
instance of a class hold that condition, but any instance
holding that condition or combination of conditions can
be recognized by a software reasoner to be a member of
the class. For example, the class Enzyme can be defined to
be any protein that catalyses a reaction. (This, of course,
excludes any catalytic RNA molecules, but that's another
story.) Thus, the ability to catalyze a reaction is enough to
recognize a protein as an enzyme and all enzymes must
catalyze reactions.
As OWL classes describe sets of instances, we can use
classes to ask questions of the instance data. Description
Logic ontologies have been used in this manner before in
systems such as TAMBIS [31]. Here, we wish to ask ques-
tions about pathways. Indeed, once we have sets of path-
ways, we can perform further manipulations upon them
to ask further questions. Some example questions a biol-
ogist might wish to ask are:
Image showing the ontology and the mapping of a reaction from the glycolysis pathway Figure 5
Image showing the ontology and the mapping of a reaction from the glycolysis pathway. The black arrows indicate the physical 
entity subclasses of the reaction (protein and smallMolecule). The green and blue arrows refer to interaction subclasses. The 
green arrows indicate the properties of the catalysis class (CONTROLLER and CONTROLLED); the blue arrows indicate the 
properties of the class biochemicalReaction (LEFT, RIGHT, and E.C.#)BMC Bioinformatics 2007, 8(Suppl 3):S3 http://www.biomedcentral.com/1471-2105/8/S3/S3
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1. What pathways include the vitamin D receptor? That is,
what are the pathways that include a step in which the
vitamin D receptor participates?
2. What pathways are implied by the gene products of a set
of genes? That is, what is the set of pathways that have
steps in which a gene product from a set of genes partici-
pates?
3. What pathways involve cholesterol? That is, what is the
set of pathways in which there is a step that involves cho-
lesterol?
4. What pathways would I expect to see invoked when I
add 9-cis-retonic acid to a macrophage? That is, what set
of pathways are used in a macrophage and are induced by
addition of 9-cis-retonic acid?
5. What pathways exist in a particular cell? That is, what is
the set of pathways known to exist in a particular cell type?
6. What pathways exist within particular types of tissues?
That is, what is the set of pathways that is the union of all
sets of pathways seen in the range of cell types in a tissue?
7. What pathways involve retinoic acid or any of its deriv-
atives (it's oxidative breakdown products)? That is, the set
of pathways in which retinoic acid or any of its derivatives
is a component of a pathway step?
8. What databases do these instances come from? That is,
what is the set of databases from which any of the
instances in a set of pathways originate?
9. We have a phenotype, what are the pathways which
involve a specified metabolite that might be linked to this
effect? That is, what is the set of pathways that is known to
be linked to a particular phenotype?
10. What are the metabolites that a set of pathways has in
common? That is, what is the set of small molecules that
participate in a step of a set of pathways?
11. What is the set of pathways that are active in the par-
ticular time interval?
This list is by no means exhaustive, but provides a sample
of the kind of questions that one might ask of pathway
data. Other researchers who have attempted to ask such
questions have used the BioPAX data in its RDF form and
used RDF technology, such as RDF stores and RDF query
languages to ask these questions [32]. Here we wish to
explore the utility of the ontology itself for not only pro-
viding some kind of common conceptualization for these
data but also as the mechanism for querying these data.
Current use of the BioPAX ontology does not take advan-
tage of what OWL can do. Rather than a static artifact, we
can use the BioPAX ontology as a dynamic, flexible soft-
ware component. We can use it to recover sets of pathways
Image showing the mapping of the biochemical reaction beta-D-glucose-6-phosphate <=> D-fructose-6-phosphate from the glycol- ysis pathway in BioCarta to BioPAX [30] Figure 6
Image showing the mapping of the biochemical reaction beta-D-glucose-6-phosphate <=> D-fructose-6-phosphate from the glycol-
ysis pathway in BioCarta to BioPAX [30]. Figure courtesy of Michael Cary and Gary Bader.BMC Bioinformatics 2007, 8(Suppl 3):S3 http://www.biomedcentral.com/1471-2105/8/S3/S3
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based on biological descriptions inherent in the BioPAX
ontology itself.
Results
For testing, we used a small subset of the BioCyc BioPAX
data, the Argobacterium tumefaciens C58 (ArgoCyc) glyc-
olysis pathway. We chose a subset where we could count
the number of instances we expected to retrieve. The fol-
lowing are defined classes, we created, which function as
queries over the instance data (OWL individuals):
1. ATPSmallMolecule
2. ATPPhysicalEntityParticipant
3. ATPBiochemicalReaction
4. ATPCatalysis
5. ATPPathwayStep
6. PathwayInvolvingATPBiochemicalReaction
Each of these classes is described such that instances are
retrieved based on the involvement of ATP. So, small mol-
ecules that are ATP, reactions involving ATP, pathway
steps involving ATP and finally pathways involving ATP
are all retrieved from the database. The following list
shows what was returned for each of the classes defined
above:
ATPSmallMolecule
Returns:
smallMolecule127380 ("ATP")
ATPPhysicalEntityParticipant
Returns:
phys-ent-participant127589
("6-phosphofructokinase")
ATPPathwayStep
Returns:
pathwayStep127652 ("glycolysis I")
pathwayStep127583 ("glycolysis I")
pathwayStep127696 ("glycolysis I")
ATPCatalysis
Returns:
catalysis127540 ("pyruvate kinase")
catalysis127476 ("phosphoglycerate kinase")
ATPBiochemicalReaction
Returns:
biochemicalReaction127530
("Pyruvate kinase")
biochemicalReaction127468
("Phosphoglycerate kinase")
biochemicalReaction127378
("6-phosphofructokinase")
PathwayInvolvingATPBiochemicalReaction
Returns:
pathway127351 ("glycolysis I")
Note: The string value of the BioPAX property NAME is
shown in parentheses for the readers' convenience. The
OWL file used in this example is additional file 1. All files
used in this paper needed to be altered from their original
version. The modified files are made available on the
EMPWR.org website. Please see the section on Debugging
the BioPAX Ontology in the Methods section for details
about the modifications. Having shown that our
approach succeeded with these tests, we wished to query
the HumanCyc BioPAX instance data with questions that
are more biologically appealing. We developed classes
that described the following instances and used data from
2 pathways that were extracted from HumanCyc, the cho-
lesterol biosynthesis pathway and the superpathway of
glycolysis, pyruvate dehydrogenase, TCA, and glyoxylate
bypass pathway. The files used in this example are addi-
tional file 2 and additional file 3.
1. PathwayInvolvingATPBiochemicalReaction or
PathwayInvolvingH2OBiochemicalReaction or
PathwayInvolvingNADPlusBiochemicalReaction or
PathwayInvolvingOxygen2BiochemicalReaction
￿ pathway79839, pathway17042 (pathway79839 is cho-
lesterol biosynthesis, and pathway17042 is the superpath-BMC Bioinformatics 2007, 8(Suppl 3):S3 http://www.biomedcentral.com/1471-2105/8/S3/S3
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way of glycolysis, pyruvate dehydrogenase, TCA, and
glyoxylate bypass.)
2. CholesterolSmallMolecule
￿ smallMolecule79898 ("cholesterol")
3. ATPCatalysis
￿ catalysis17524, catalysis17369, catalysis17161,
catalysis17364, catalysis17718, catalysis17511,
catalysis17173, catalysis17149, catalysis17353
4. H2OCatalysis
￿ catalysis17789, catalysis17767, catalysis17772,
catalysis17778, catalysis17801
5. NADPlusCatalysis
￿ catalysis17818, catalysis17328, catalysis17333,
catalysis17304, catalysis17279, catalysis17686,
catalysis17338, catalysis17289, catalysis17831,
catalysis17309, catalysis17274, catalysis17087,
catalysis17294, catalysis17299, catalysis17284,
catalysis17826
6. Oxygen2Catalysis
￿ catalysis80292, catalysis80235, catalysis80214,
catalysis80101, catalysis80170, catalysis80116,
catalysis79970, catalysis80161, catalysis80246,
catalysis80152, catalysis80125
The following used the entire HumanCyc data set, which
can be found at [33]. As we are working with various
builds of Protege4Alpha, performance was an issue and
made it impractical to use the entire data set for much of
this work.
1. Class: PathwayInvolvingCholesterolBiochemicalReac-
tion
￿ pathway106063
2. Class: NoradrenalinePathwayStep
￿ pathwayStep106053 pathwayStep106054
3. Class: PathwayInvolvingNoradrenalineBiochemicalRe-
action
￿ pathway106051
4.  Class:  PathwaysInvolvingH2OBiochemicalReaction
(HumanCyc contains 185 pathways, of them, 115 involve
H2O)
￿ pathway106411 pathway106531 pathway105873
pathway106934 pathway106008 pathway105463
pathway105937 pathway106460 pathway105742
pathway106804 pathway106785 pathway106682
pathway106296 pathway105696 pathway107053
pathway106919 pathway106379 pathway106331
pathway106791 pathway106477 pathway106150
pathway107067 pathway106123 pathway105810
pathway106321 pathway106451 pathway106689
pathway105689 pathway106851 pathway105642
pathway106544 pathway106002 pathway106421
pathway105825 pathway106354 pathway106057
pathway105681 pathway106037 pathway106829
pathway105734 pathway106394 pathway106206
pathway106249 pathway106565 pathway106306
pathway105667 pathway107061 pathway106585
pathway106365 pathway107134 pathway106717
pathway106656 pathway106581 pathway107152
pathway107079 pathway106553 pathway106384
pathway107093 pathway106814 pathway106389
pathway107017 pathway105704 pathway105715
pathway105798 pathway106571 pathway105955
pathway106284 pathway106268 pathway105792
pathway107031 pathway106645 pathway106776
pathway105457 pathway106337 pathway105452
pathway106908 pathway106807 pathway106833
pathway106981 pathway105885 pathway106195
pathway106416 pathway106432 pathway106499
pathway106428 pathway106729 pathway105473
pathway105727 pathway106596 pathway105677
pathway107180 pathway105721 pathway106467
pathway105655 pathway106548 pathway107036
pathway106219 pathway106939 pathway106399
pathway105979 pathway106756 pathway105966
pathway106494 pathway106347 pathway106441
pathway105674 pathway105928 pathway106671
pathway106664 pathway105971 pathway106028
pathway105684 pathway106015 pathway105757
pathway106634
5. ￿ PathwayInvolvingNADPlusBiochemicalReaction
(PathwayInvolvingNADPlusBiochemicalReaction Equiv-
alentTo bp2:pathway and bp2:PATHWAY-COMPO-
NENTS some NADPlusPathwayStep Resutls: 60
pathways)
pathway106389 pathway107017 pathway105798
pathway106531 pathway105873 pathway105955
pathway106460 pathway106750 pathway105742
pathway106268 pathway107053 pathway106645
pathway106776 pathway106919 pathway105457BMC Bioinformatics 2007, 8(Suppl 3):S3 http://www.biomedcentral.com/1471-2105/8/S3/S3
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pathway106379 pathway106130 pathway106150
pathway107067 pathway106765 pathway106451
pathway105810 pathway106689 pathway106981
pathway106902 pathway106954 pathway106170
pathway106421 pathway106416 pathway106432
pathway106428 pathway106729 pathway105825
pathway106037 pathway106596 pathway106394
pathway105734 pathway106467 pathway107172
pathway106219 pathway105667 pathway105979
pathway106585 pathway107134 pathway106365
pathway105966 pathway106486 pathway106441
pathway106656 pathway107079 pathway106970
pathway106949 pathway106553 pathway106617
pathway106671 pathway106028 pathway106384
pathway106015 pathway107093 pathway106634
6. PathwayInvolvingH2OBiochemicalReaction and
PathwayInvolvingNADPlusBiochemicalReaction (This is
the intersection of the two classes.
PathwayInvolvingH20BiochemicalReaction EquivalentTo
bp2:pathway and bp2:PATHWAY-COMPONENTS some
H2OPathwayStep  and  PathwayInvolvingNADPlusBio-
chemicalReaction EquivalentTo bp2:pathway and
bp2:PATHWAY-COMPONENTS some NADPlusPathway-
Step)
￿ Returns the 49 pathways that contain both H2O and
NAD+
pathway106389 pathway107017 pathway105798
pathway106531 pathway105873 pathway105955
pathway106460 pathway105742 pathway106268
pathway107053 pathway106645 pathway106776
pathway105457 pathway106919 pathway106379
pathway106150 pathway107067 pathway105810
pathway106451 pathway106689 pathway106981
pathway106421 pathway106432 pathway106416
pathway106428 pathway106729 pathway105825
pathway106037 pathway106596 pathway106394
pathway105734 pathway106467 pathway106219
pathway105667 pathway105979 pathway106585
pathway106365 pathway107134 pathway105966
pathway106441 pathway107079 pathway106656
pathway106553 pathway106671 pathway106028
pathway106015 pathway106384 pathway107093
pathway106634
Our results are correct for the data used. We retrieve all
and only those described in the classes. It might seem
unusual that only one human pathway involves choles-
terol, but that is the only pathway in HumanCyc that
appears to involve cholesterol. These results were checked
by hand inspecting the RDF data and via the HumanCyc
Web site [34]. We also see that once we have sets of path-
ways, we can quickly derive further sets, for instance by
forming the intersection of two sets. This in itself forms a
sophisticated way of manipulating pathway data. Ideally,
we would like to have used more than one BioPAX com-
pliant resource. Unfortunately, the size of these data run-
ning only in memory in the Protégé tool is unsustainable.
To combine data from more than one source would mean
more work at the start of this process. When defining
physicalEntityParticipant, we would have to make more
sophisticated definitions of the small molecules and other
physical entities that participate in biological processes.
We see only one pathway, but HumanCyc contains a
series of "reactions without pathways." These reactions
map to the following pathways that do appear in KEGG
(Table 1). Were we to use both resources at once, we
might well retrieve all the appropriate answers.
Discussion
Our experiments show that we can use the BioPAX ontol-
ogy to describe sets of pathways. These pathway sets can
be further manipulated to derive new sets of pathways.
Using the ontology, we can describe these sets according
to biological phenomena. This means we can formulate
descriptions along the lines of "the set of pathways
implied by these genes"; "the set of pathways implied by
these up-regulated genes"; etc. This gives a direct link back
to the kind of questions described in the section 'An
Experiment with BioPAX'. We can answer the majority of
the example biological questions outlined in the section
'An Experiment with BioPAX'. The BioPAX ontology has
no notion, as yet, of Gene. This means any question with
gene as the basis cannot be answered. The development of
BioPAX level three should include the notion of gene, so
it is likely that this range of question will be able to be
formed. The other notable questions that cannot be asked
Table 1: The reactions not associated with pathways in HumanCyc but for which there was a corresponding pathway in KEGG.
HumanCyc Reaction KEGG Pathway and corresponding reaction
cholesterol + an acyl-CoA = cholesterol ester + coenzyme A R0146 EC 2.3.1.26 in Bile acid biosynthesis pathway
O2 + NADPH + cholesterol = H2O + NADP± + 7α-hydroxycholesterol R01453 EC 1.14.13.- in biosynthesis of steroids
NADP+ + cholesterol = 7-dehydro-cholesterol + NADPH R01456 EC 1.3.1.21 in biosynthesis of steroids pathway
O2 + a reduced adrenal ferredoxin + cholesterol = H2O + an oxidized adrenal 
ferredoxin + 4-methylpentanal + pregnenolone
R02724 EC 1.14.15.6 in C21-Steroid hormone metabolism
The numbers prefixed by R are the reaction numbers in the KEGG database.BMC Bioinformatics 2007, 8(Suppl 3):S3 http://www.biomedcentral.com/1471-2105/8/S3/S3
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are those involving some temporal aspect. Time intervals
are not part of the BioPAX ontology and are absent from
much of the data BioPAX attempts to reconcile. The other
of our example questions can be answered, even though
somewhat clumsily. Any query that is predicated upon
using terms from external controlled vocabularies (such
as cellular location) are somewhat ugly (in ontological
terms). We have not, as yet, explored whether we can
answer questions asking for pathways that involve a small
molecule or any of its derivatives.
In these experiments we did not actually integrate any
data from more than one resource. We only queried data
from one resource. Proper integration is our next step. We
know this is possible by writing more complex definitions
in the current style. This would simply use constructs such
as hasName (name-in-db-1 or name-in-db2). This is per-
forming the instance reconciliation we stated as one of the
necessary steps for true integration. This approach obvi-
ously has its scalability issues. Until such reconciliation is
done by the bioinformatics as a whole it will remain as a
significant barrier to analytical work.
The points for discussion arising from this work are not so
much that it worked, but what we had to do in order for it
to work. Examining what we had to do in order to make
our approach work, an approach that should be inherent
to BioPAX due to its use of a Description Logic, is inform-
ative to the future directions of BioPAX.
First, however, a question that should be asked is whether
this approach is at all useful or justified? Scalability is an
issue. We performed these experiments in memory and
this limits the number of instances that can be queried.
Tools such as the Instance Store [35] would limit number
of individuals to disk space and be, therefore, to all intents
limitless. We are aware the current released version of
instance Store does not support roles between individuals.
Prototype versions do, however, exist that support such
constructs. A significant advantage of our approach is the
manner of describing the class of instances to be retrieved.
Directly modeling the query in the ontology allows the
model to be used directly to make the query [31]. The
major barrier we encountered in achieving our goal was
the ontology itself. As already pointed out [36,37], the
BioPAX ontology conflates descriptions of biology and
descriptions of the data about biology [32]. It is not that
modeling the data is wrong, but doing both at the same
time and place in a model makes it difficult to use the
description to ask questions. The real issue, however, is
exemplified by pathwayStep which is a kind of utilityClass
used for purposes of pathway visualization, but also as a
real step in a real pathway. If a class is necessary for mod-
eling the data then it should be a utility; if it is needed for
describing biology, then it should be in the "biological"
part of the ontology. As many of these classes are disjoint
(utilityClass and entity, for example) then it becomes very
difficult to formulate questions (see section An experi-
ment with BioPAX).
Our definitions are in terms of the data about reality, not
the reality itself. We have already observed that defining a
class ATPSmallMolecule as an instance that has the name
"ATP" is not elegant to say the least (see section 'An Exper-
iment with BioPAX'). ATP is really defined by a certain
chemical structure of atoms and covalent bonds. Using
the name, however, was one of only two ways we could
use the BioPAX instance data to define ATPSmallMole-
cule. In this experiment, we are restricted to what the Bio-
PAX instance data allowed us to do.
BioPAX allows for use of other controlled vocabularies to
label things in its instance data. For example, locations are
given by an instance of controlledVocabularyTerm. This
sort of works, but what we are stating is that a molecule's
location is a term of a controlled vocabulary, not some
part of a cell. Much better, in modeling terms, would be to
include or refer to external ontologies and use them as
ontologies. So, for physical entities, portions of the OBO
version of the Chemicals of Biological Interest (ChEBI)
dictionary [38] would be introduced. Proteins, RNA and
DNA, etc. might have cellular locations provided by the
GO's cellular location ontology [39]. In such a case, the
actual BioPAX ontology would be very small, but very
large by its use of other ontologies. Finally, BioPAX's use
of external controlled vocabularies as data items means
that the semantic structure of those external vocabularies
cannot be exploited. When we ask for pathways involving
cholesterol, we retrieve only those involving cholesterol
and only cholesterol. This is, of course, fine if that's all we
want. In the current situation, asking for cholesterol,
kinds of cholesterol or cholesterol derivatives is nigh-on
impossible.
What effect would inclusion of external ontology as ontol-
ogy have? We could, for example, very easily make a class
CytosolicKinaseProtein by simply referring, via restric-
tions, to instances of kinase activity and Cytosol from
GO's molecular function and cellular component ontol-
ogy respectively. Similarly, ATPSMallMolecule, instead of
being defined by the name of an individual, would simply
be an instance of the ChEBI class for ATP, namely
CHEBI:15422. Similarly, we could describe a class of
pathways by describing it as performing a biological proc-
ess of, for instance GO's Glycogen Biosynthesis.
As we describe for the case of defining ATP, we have used
what are known as nominals (individuals raised to the sta-
tus of a class) to make class definitions [40]. It would be
better modeling practice to put the class ATP as the fillerBMC Bioinformatics 2007, 8(Suppl 3):S3 http://www.biomedcentral.com/1471-2105/8/S3/S3
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of the definition. In this way we would be saying that, for
example, that any instance of a small molecule that has an
instance of the structure of ATP is an ATP small molecule.
It would be even better to have an ontology of small mol-
ecules underneath the BioPAX ontology's smallMolecule
class.
Mappings to such an ontology would have to be per-
formed as part of the conversion from client resource to
the BioPAX ontology target. Not only would this make the
ontological modeling easier, but perform reconciliation at
the level of values/instances at the same time.
What are described as "instances" in BioPAX are really
classes. All the nominals we used are really classes: ATP;
reactions; interactions; pathway steps are really entities
that describe sets of instances in the biological world. As
described, working at the class level might actually make
this work easier. Again, BioPAX has taken a database view
of instances. HumanCyc, for example, contains a data
instance of ATP. This view has been propagated into the
BioPAX ontology and instance data.
We moved pathwayStep to be a kind of pathway. In these
experiments this worked. There is an issue, however, of
whether a pathway step is a kind of pathway or a part of a
pathway. If, in our conceptualization of pathways, we can
have a single step pathway, then it is legitimate that a
pathwayStep is a kind of pathway. It would also be legiti-
mate (we can find no counter examples) that any one step
pathway is part of a greater pathway. In the end, such a
choice probably does not make any practical difference.
This brings in some upper level ontology issues. Most
upper level ontologies [41-43] make the distinction
between Continuant and Occurant (thing and process).
Pathways are processes that have physical objects as their
participants. Distinctions made at the upper level can
sometimes seem a little abstruse, but it helps make basic
distinctions, choose one's properties appropriately. It can
cause many arguments, but simply sticking to an upper
level ontology can aid consistency in modeling decisions.
Based on these discussions and on points raised during
this paper, we would advocate the following changes be
made to the BioPAX ontology:
1. The use of an upper level ontology to draw distinctions
between classes of instances, such as continuants and
occurants, independent and dependent continuants etc.
2. That the BioPAX ontology separates descriptions of data
from descriptions of biology.
3. The explicit inclusion of other ontologies to provide
classes needed to describe the data about pathways.
4. That the instances of BioPAX more reliably represent
actual instances rather than classes (see the ATP small
molecule example).
5. That a more careful use of OWL's disjoint axiom be
used throughout the ontology. The BioPAX ontology has
the basis for a well structured ontology based on trees of
primitive classes [44]. Along with the other recommenda-
tions given here, a combination of pulling apart conflated
notions and systematic use of disjunction would give a
solid foundation for querying BioPAX data.
6. Careful use of OWL semantics could make explicit
some of the semantics held within the comments of the
BioPAX ontology.
7. Careful use of OWL semantics, such that there is one
BioPAX ontology standard, not two and possibly more
with each level release.
Conclusion
In this paper we have explored the potential for the Bio-
PAX initiative and its ontology to deliver the pathway data
necessary for systems style bioinformatics enabled by e-
Science. In particular we have looked at the semantics of
such integration and how OWL-DL can be used to repre-
sent those semantics and be exploited to ask semantically
rich questions. We have used the BioPAX ontology to ask
questions that deliver sets of pathways. These pathways
themselves can then be manipulated to deliver new sets of
pathways. The ontology, using its biological aspects,
allows sets of pathways or their various components to be
described biologically. These sets of pathways can be used
as parts of approaches to many analyses. Furthermore,
until the BioPAX ontology includes the notions of gene,
sequence, chromosome and location, it will not be possi-
ble to describe pathways in some of the important ways
needed for biological investigations.
The BioPAX initiative succeeds in its basic goal of allowing
pathway interoperation. There are now multiple pathway
databases, increasing in number, whose data are compli-
ant with the BioPAX ontology. As we described, pathways
form a data nexus for modern bioinformatics in an e-Sci-
ence setting, so this is a significant achievement. The Bio-
PAX ontology acts as a model that allows a wide variety of
pathway data to be assembled according to one common
conceptualization of the domain and in one common syntax.
It does, however, fail at the level of reconciling pathway
instances. BioPAX almost provides for this by its inclusion
of external controlled vocabularies, but not in the way
really desired by this approach to data. Of course, BioPAXBMC Bioinformatics 2007, 8(Suppl 3):S3 http://www.biomedcentral.com/1471-2105/8/S3/S3
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does not even attempt to reconcile the labels used for all
the entities appearing within pathway data. This is a task
beyond its means. We have, however, the technical means
to achieve this goal, if not the will and financial means.
The current reconciliation makes it possible to query
across resources, but a deeper reconciliation would make
such querying across resources easier and significantly
powerful. Another conclusion to be drawn from this work
are ontological conclusions about the BioPAX ontology:
1. The BioPAX ontology conflates modeling of data and
modeling of biology.
2. By modeling each separately, a cleaner and easier for-
mulation of queries and description of data would be pos-
sible.
3. Raising most instance data to the class level would be a
more true reflection of the biological world, but have no
absolute effect on the queries possible. In fact, much of
the technology would be more effective and modeling
would be easier if class things were class things.
4. A modular approach to other ontologies would again
reflect the biological world and engender easier queries.
Rather than modeling other ontologies as data, importing
them as ontologies at the class level would enable richer
descriptions to be made during queries. This would have
no effect on mapping contributing resources into BioPAX.
There are, however, issues of maintenance and synchrony
of versions.
5. A closer attention to OWL semantics would make pos-
sible a greater range of queries. Problems were caused by
the misuse or lack of use of features available in the OWL
semantics.
6. Publish one BioPAX ontology; currently there are two
separate BioPAX namespaces, one for BioPAX level one
and another for BioPAX level 2.
We would advocate, therefore, a re-modeling of the Bio-
PAX ontology. This has to, of course, take the current data
providers along. Interestingly, however, much of the re-
modeling can be accomplished with little disruption.
Many of the current classes are the ones needed. The
changes made in these experiments did not necessitate
any changes to the data. Simple re-arrangements of the
classes are simply reflected automatically in the instance
data. New asserted classes would, however, mean changes
in instance data encoding.
The BioPAX initiative is an exemplar of the needs of mod-
ern, systems level bioinformatics in an industrial, e-Sci-
ence form. It is typical of bioinformatics data in being
highly distributed and highly heterogeneous at all levels.
The BioPAX ontology, despite flaws, makes it possible to
deliver sets of pathways, described and queried based on
biology to bioinformatics analyses.
Methods
We have the following resources from which to ask these
questions:
￿ The BioPAX ontology.
￿ The BioPAX data from HumanCyc [23].
￿ The Pellet [15] and FaCT++ [14] reasoners.
￿ Protégé 4Alpha [45].
We use both the BioPAX level one and level two ontolo-
gies. Any new classes we make, we have placed in a addi-
tional file 4. This pays some respect to the BioPAX
observance that no new classes should be made; with a
module, all our classes can be removed easily.
We wish to form classes that represented at least some of
the types of questions listed above. This does, however,
break one of the directives in the BioPAX documentation
(p.56,57) [11]: "changing the ontology is not recom-
mended if the instance data are meant to be shared.". We
ignore this mandate simply because we wish to use the
Description Logic machinery with the ontology in order
to answer questions. Having built an ontology, provided
a large resource of instances, why not use the computa-
tional power of OWL-DL? Putting our queries into a sep-
arate module means that in effect we do not change the
BioPAX ontology as far as any other users are concerned.
In order to answer the kinds of questions listed above, we
form new classes that describe sets of entities involved in
pathways in the BioPAX instances files. These are sets of
pathway instances described in terms of the classes and
instances that already exist in the ontology and the
instance data. This is typical conceptual lego [46] in that the
building blocks of the classes already exist and these are
built up into more complex class descriptions to answer
questions.
The general plan is, therefore, to create some classes that
describe pathways. These pathways will be described in
terms of, for instance: A catalysis they perform; a macro-
molecule they involve; a small molecule they involve; etc.,
as seen in the section BioPAX. The BioPAX ontology
describes these types of entities.
The BioPAX ontology also has a broad collection of prop-
erties or relationships that link the instances of theseBMC Bioinformatics 2007, 8(Suppl 3):S3 http://www.biomedcentral.com/1471-2105/8/S3/S3
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classes together. In the BioPAX ontology, these have been
encoded in two ways:
1. As restrictions on classes. This means that if any
instance of the property exists on an instance of the class,
then each and every instance of that class must hold that
property.
2. As domain constraints. This means that if any instance
is found to hold that property, then it is implied to be an
instance of the domain class.
This gives a flexible approach to encoding knowledge. The
first statement is very strong and the second somewhat
weaker, but with potentially profound effects [46]. For
example, the BioPAX ontology states that each and every
pathway must have a NAME. This is in the form of a restric-
tion. The property PATHWAY-COMPONENTS is encoded
with domain and range constraints. The domain is path-
way and the range is interaction or pathwayStep or path-
way. In OWL, this means that any instance that holds a
property PATHWAY-COMPONENTS is reasoned to be a
member of the class pathway. Note that this is not saying
that all pathways must have a pathwayStep or an interac-
tion. In reality they might well do so, but in BioPAX data
it is possible for a pathway to be described without there
being any data about its component steps or interactions.
This is a compromise between modeling some perceived
biological reality and modeling the data. Essentially, we
can interpret this as meaning "we do not know what the
parts of a pathway are, but we know the pathway exists.".
Encoding BioPAX pathways in classes
Our goal is to describe pathways. The following sequence
of connections exist:
￿ Pathways have pathway components that are pathway
steps.
￿ Pathway steps are made of step interactions.
￿ Step interactions are made up of interactions (physical
interactions such as catalysis, modulation, biochemical
reaction, complex assembly and transport, or a pathway).
￿ Interactions have participants.
￿ Participants are physical entities of the class small mol-
ecule, protein, complex, RNA and DNA.
These classes have other elements to their descriptions,
but here we are principally concerned in how to join
together descriptions to describe sets of pathway instances.
We wish to retrieve data that are represented as instances.
So, our classes have to have enough description by which
to recognize instances as members of the class. This means
we have to use conditions that are both necessary and suf-
ficient. We will discuss the ontological soundness of this
in the discussion section.
If we wish to have a class for the small molecule ATP, we
do the following:
Class: ATP
EquivalentTo: physicalEntityParticipant
that NAME value "ATP"
We are saying that any individual that is a smallMolecule
and has the NAME "ATP" is a member of the class ATP.
Obviously this is no real definition of the class ATP. It is,
however, enough to satisfy the query "give me ATP chem-
ical" in this particular data set. The BioPAX model uses ref-
erences to the contents of the originating database that
detail the primary identifier within a resource for a partic-
ular entity. We could use a combination of database iden-
tifier and instances identifier to define ATPSmallMolecule
(or any other such instance). This could arguably be better
modeling, but in this case has the same effect. We can
extend our definition to accommodate other data descrip-
tions. All other restrictions on the physicalEntityPartici-
pant class can remain unspecified; they are inherited, but
do not need to be specialized unnecessarily. One of
OWL's strong points is its ability to model incomplete
knowledge [16]. We can use terms from controlled vocab-
ularies to help us define classes of physical entity. We can,
for example, describe a class of all physicalEntityPartici-
pant that occur in the cytosol of cells. One of the restric-
tions on physicalEntityParticipant is that it has a location
and that the location is an instance of controlledVocabu-
laryTerm. The BioPAX data has an instance of openCon-
trolledVocabulary that is cytosol. By making this
restriction both necessary and sufficient, we can make a
class with enough description in order to recognize any
BioPAX instance that has a cytosolic location. Again, this
is not ontologically satisfactory (see Discussion section).
So, we can create physicalEntityParticipant of various
kinds. Once we have these classes, we can begin to make
more pathway orientated classes. A biochemicalReaction
has PARTICIPANTS that are physicalEntityParticipant.
The PARTICIPANTS property of biochemicalReaction has
two sub-properties, LEFT and RIGHT that describe physi-
calEntityParticipant on either side of a reaction. Using the
super-property, it is easy to describe reactions that involve
any kind of physicalEntityParticipant on either side of the
reaction in any cellular location. In the example below,
bp2: is a prefix used for QNames, the qualified name of
the class, which is its URI.BMC Bioinformatics 2007, 8(Suppl 3):S3 http://www.biomedcentral.com/1471-2105/8/S3/S3
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Class: ATPSmallMolecule
EquivalentTo:
bp2:smallMolecule that
bp2:NAME value "ATP" string
Class: ATPBiochemicalReaction
EquivalentTo:
bp2:biochemicalReaction that
bp2:LEFT some
ATPPhysicalEntityParticipant
Class: ATPCatalysis
EquivalentTo:
bp2:catalysis that
bp2:CONTROLLED some
ATPBiochemchemicalReaction
Class: ATPPEP
EquivalentTo:
bp2:physicalEntityParticipant that
bp2:PHYSICAL-ENTITY some
ATPSmallMolecule
Class: ATPPathwayStep
EquivalentTo:
bp2:pathwayStep that
bp2:STEP-INTERACTIONS some
(ATPCatalysis or ATPBiochemchemicalReaction)
Class: PathwayInvolvingATPBiochemicalReaction
EquivalentTo:
bp2:pathway that
bp2:PATHWAY-COMPONENTS some
ATPPathwayStep
Debugging the BioPAX ontology
In the previous section we have described how we make
the classes that act as our queries. In this section we
describe how we make the BioPAX ontology retrieve the
appropriate instances. Each time we make a new class, we
use the reasoner to check that the ontology is logically
consistent; that the new class is placed where we expect it
to be placed; and that expected instances from a test set of
instances are recovered by the query. At almost every stage
of development, we uncovered defects in the BioPAX
ontology. Some of these were inappropriate use of OWL
and others are deeper ontological modeling issues. Here
we list these issues and note the corresponding alterations
we made to the BioPAX ontology in order to enable it to
function with the Description Logic reasoners.
￿ BioPAX has two ontologies; level one and level two.
Level two extends level one with some extra classes, such
as DNA and physicalInteraction. All the classes from level
one also appear in the level two module. In OWL, how-
ever, a classes identity is its URI; the display label is just a
display label. Unfortunately, the classes from level one
that are replicated in level two had a different URI and are
therefore interpreted as different classes. If the same URI
appears in two different modules, the OWL machinery
simply works it all out. In this case, however, we find two
classes instead of one for all the classes in level one. This
was easily fixed by changing the all the URIs to be level
two URIs. While this was easily fixed with a global replace,
it would be better for the BioPAX ontology to be one
ontology.
￿ There is a major division in BioPAX between utilityClass
and entity (see BioPAX section) and these classes are dis-
joint. One of the classes we used in the construction of
new classes (physicalEntityParticipant) is a kind of utility-
Class. As physicalEntityParticipant are defined in terms of
physicalEntity, this caused the reasoner to return incon-
sistency errors. Consequently, the physicalEntityPartici-
pant was moved from utilityClass to become a subclass of
physicalEntity.
￿ A similar inconsistency occurred when pathwayStep was
analyzed. We made a pathwayStep a subclass of pathway.
￿ The disjoint axiom between physicalEntityParticipant
and physicalEntity was removed.
￿ The disjoint axiom from pathway and interaction was
removed.
￿ The class physicalEntity was made disjoint with pathway
and interaction.BMC Bioinformatics 2007, 8(Suppl 3):S3 http://www.biomedcentral.com/1471-2105/8/S3/S3
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￿ Many properties have ranges that are other BioPAX
classes. For example, the property PHYSICAL-ENTITY has
the domain of physicalEntityParticipant. physicalEntit-
yParticipant itself has a restriction of PHYSICAL-ENTITY
max 1 owl:Thing. The OWL 1.1 standard only allows car-
dinality restraints that say any instance holds n copies of
this property. Implicitly, the instance that qualifies this car-
dinality is owl:Thing. That is, only one property linking an
instance of physicalEntityParticipant to an instance of
owl:Thing can be present. In theory, this means any
instance, a HoverCraft for example, can act as successor to
the PHYSICAL-ENTITY property. That is not what what we
want. What we want is qualified cardinality restraints,
where we specify what type of instance acts as a successor.
In this case, we want an instance of physicalEntity to act as
successor. Changing BioPAX from the OWL 1.0 cardinal-
ity constraint to the more precise qualified cardinality
restrictions (QCR) causes inconsistency errors with some
reasoners. FaCT++ [14] can reason over QCR that are now
part of the proposed OWL 1.1 specification, but Pellet at
the time of writing, does not do so [15]. We wished to use
QCR in our version of BioPAX so that we could make
appropriate definitions. A ProteinPhysicalEntityPartici-
pant is defined in terms of a restriction PHYSICAL-
ENTITY max 1 protein. Simple cardinality restrictions
would not allow us to do this step that is vital for our
needs.
￿ In biopax-level1.owl, the property DELTA-G is defined
as a DatatypeProperty and in biopax-level2.owl, it is
defined as an ObjectProperty. The file biopax-level2.owl
was modified to use the DatatypeProperty definition.
Without this correction, this mistake causes the merged
level 1 and level 2 ontologies to be OWL-Full.
￿ The following two errors cause the reasoner to complain
about redefinitions of XML schema types and thus make
the ontology OWL-Full (again):
- A fragment of an orphaned range definition needs to be
removed from the biopax level 2 file: <owl:DatatypeProp-
erty rdf:about="http://www.w3.org/2000/01/rdf-
schema#range"/>.
- All occurrences of the string &xsd; need to be replaced
with the string xsd:.
Changes were also needed in the HumanCyc.owl file
(which contains the instance data) in order to run these
experiments:
￿ The name of the file was changed from biopax.owl to
HumanCyc.owl. This was done exclusively for the conven-
ience of the authors who were working with multiple
organism and pathway files. SRI, International Inc. The
supplier of the BioCyc family of databases reuses the
filename biopax.owl for all BioPAX formatted files.
Whether they are one pathway or all the pathways within
an organism, all are all named biopax.owl. This is only a
problem for the human reader; the important name, i.e.
the namespace is defined within the file.
￿ The RDF data type definitions were missing from
DELTA-G, MOLECULAR-WEIGHT and STOICHIOMET-
RIC-COEFFICIENT. This was corrected by adding
rdf:datatype=xsd:double to each instance.
￿ All occurrences of the string level1 were replaced with
level2, being the more recent and complete BioPAX ontol-
ogy. This was an easy work around the problem that Bio-
PAX level 1 and BioPAX level 2 are two independent
ontologies (namespaces) notwithstanding the intent to be
backward compatible. While this is a BioPAX mistake, it
was easier in this case to alter the reference in the data.
Not all of these changes are ontologically valid. Most of
them were made simply to get the queries to work. Also,
to make the ontology more explicit, we used the QCR fea-
ture from the proposed OWL 1.1 extension [47]. Obvi-
ously, BioPAX as a project will not use non-standard
expressivity. We simply use it here as part of our experi-
ment.
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